Susquehanna International Group
RXRX icon

Susquehanna International Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Susquehanna International Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13M Sell
4,225,277
-170,827
-4% -$660K ﹤0.01% 2740
2025
Q4 		$18M Sell
4,396,104
-993,072
-18% -$4.92M ﹤0.01% 2325
2025
Q3 		$26.3M Buy
5,389,176
+2,183,837
+68% +$11.5M ﹤0.01% 1916
2025
Q2 		$16.2M Buy
3,205,339
+1,155,728
+56% +$5.68M ﹤0.01% 2242
2025
Q1 		$10.8M Buy
2,049,611
+382,622
+23% +$2.79M ﹤0.01% 2427
2024
Q4 		$11.3M Buy
1,666,989
+597,390
+56% +$4.02M ﹤0.01% 2514
2024
Q3 		$7.05M Sell
1,069,599
-297,031
-22% -$2.13M ﹤0.01% 3076
2024
Q2 		$10.2M Buy
1,366,630
+532,758
+64% +$4.65M ﹤0.01% 2457
2024
Q1 		$8.31M Buy
833,872
+469,674
+129% +$5.23M ﹤0.01% 2880
2023
Q4 		$3.59M Buy
364,198
+56,365
+18% +$402K ﹤0.01% 4281
2023
Q3 		$2.35M Buy
307,833
+210,048
+215% +$2.1M ﹤0.01% 4826
2023
Q2 		$730K Sell
97,785
-106,618
-52% -$746K ﹤0.01% 7421
2023
Q1 		$1.36M Buy
204,403
+142,403
+230% +$1.13M ﹤0.01% 6035
2022
Q4 		$478K Sell
62,000
-24,055
-28% -$236K ﹤0.01% 7983
2022
Q3 		$916K Buy
86,055
+58,570
+213% +$593K ﹤0.01% 6858
2022
Q2 		$224K Sell
27,485
-25,342
-48% -$170K ﹤0.01% 10348
2022
Q1 		$378K Sell
52,827
-152,899
-74% -$1.62M ﹤0.01% 9686
2021
Q4 		$3.52M Buy
205,726
+88,466
+75% +$1.66M ﹤0.01% 4366
2021
Q3 		$2.7M Buy
117,260
+66,614
+132% +$1.89M ﹤0.01% 5185
2021
Q2 		$1.85M Buy
+50,646
New +$1.5M ﹤0.01% 6094

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's RXRX Position: Q1 2026 in Review

Susquehanna International Group reduced its Recursion Pharmaceuticals (RXRX) stake by 3.9% in Q1 2026, selling an estimated $660K and leaving 4,225,277 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Susquehanna International Group first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $26.3M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Susquehanna International Group held 4,225,277 shares of Recursion Pharmaceuticals worth $13M as of Q1 2026.
  • Susquehanna International Group sold 170,827 Recursion Pharmaceuticals shares in Q1 2026, an estimated $660K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2740 holding.
  • Susquehanna International Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's Recursion Pharmaceuticals position peaked at $26.3M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.